Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Arq. gastroenterol ; 54(1): 51-56, Jan.-Mar. 2017. tab, graf
Article in English | LILACS | ID: biblio-838823

ABSTRACT

ABSTRACT BACKGROUND Periportal fibrosis is the major pathological consequence of the Schistosoma mansoni infection. OBJECTIVE To evaluate the accuracy of serum markers and to construct an index to assess fibrosis. METHODS Patients (n=116) with schistosomiasis were evaluated by ultrasound scan and measurements of serum levels of aminotransferases, γ-glutamyl transferase, alkaline phosphatase, hyaluronic acid, cytokines and platelets. Ultrasound images were used to evaluate the fibrosis using Niamey's classification and identified 19 patients without periportal fibrosis (patterns A and B), 48 with mild to moderate fibrosis (C and D) and 49 with advanced fibrosis (E and F). RESULTS Using multivariate analysis, a model was created, which involved alkaline phosphatase and platelets and could separate patients with different patterns of fibrosis. This index showed a better performance in separating patients without fibrosis from with advanced periportal fibrosis. The biological index showed an area under the ROC curve of 1.000. Using values below the lowest or above the highest cut-off point, the presence or absence of advanced fibrosis could be predicted in all patients. CONCLUSION The index constructed can be used to separate patients with different patterns of periportal fibrosis, specially to predict advanced fibrosis in schistosomiasis patients.


RESUMO CONTEXTO A fibrose periportal é a maior consequência patológica da infecção pelo Schistosoma mansoni. OBJETIVO Avaliar a acurácia de marcadores séricos e construir um índice para avaliar a fibrose. MÉTODOS Pacientes (n=116) com esquistossomose foram avaliados pela ultrassonografia e dosados os níveis de aminotransferases, γ-glutamil transferase, fosfatase alcalina, ácido hialurônico, citocinas e plaquetas. Imagens de ultrasom foram utilizadas para avaliar a fibrose através de classificação de Niamey e identificados 19 pacientes sem fibrose periportal (padrão A e B), 48 com fibrose média a moderada (C e D) e 49 com fibrose avançada (E e F). RESULTADOS Através de análise multivariada, um modelo foi criado, que envolveu a fosfatase alcalina e plaquetas e conseguiu separar pacientes com diferentes padrões de fibrose periportal. Este índice mostrou um melhor desempenho em separar pacientes sem fibrose dos pacientes com fibrose avançada. O índice biológico mostrou uma área sob a curva ROC de 1,000. Usando valores infereiores e acima do ponto de corte, a presença ou ausência de fibrose avançada pode ser prevista em todos os pacientes. CONCLUSÃO O índice construído pode ser usado para separar os pacientes com diferentes padrões de fibrose periportal, especialmente para prever fibrose avançada em pacientes com esquistossomose.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Aged , Young Adult , Schistosomiasis mansoni/blood , Schistosomiasis mansoni/diagnostic imaging , Biomarkers/blood , Liver Cirrhosis/blood , Liver Cirrhosis/diagnostic imaging , Severity of Illness Index , Blood Platelets , Schistosomiasis mansoni/complications , Predictive Value of Tests , Cytokines/blood , Sensitivity and Specificity , Alkaline Phosphatase/blood , gamma-Glutamyltransferase/blood , Transaminases/blood , Hyaluronic Acid/blood , Liver Cirrhosis/parasitology , Middle Aged
2.
Braz. j. infect. dis ; 20(3): 262-266, May.-June 2016. tab
Article in English | LILACS | ID: lil-789476

ABSTRACT

Abstract Background Hepatitis E virus (HEV) can cause chronic infection with rapid progression to liver cirrhosis in immunocompromised patients. HEV seroprevalence in patients with Schistosoma mansoni in Brazil is unknown. We evaluated the prevalence of past or present HEV infection in schistosomiasis patients in Recife, Pernambuco, Brazil. A total of 80 patients with Schistosoma mansoni were consecutively enrolled in a cross-sectional study. Serum samples were tested for the presence of anti-HEV IgG antibodies by enzyme immunoassay (Wantai anti-HEV IgG, Beijing, China) and for the presence of HEV RNA using real time reverse transcriptase-polymerase chain reaction with primers targeting the HEV ORF2 and ORF3. Clinical and laboratory tests as well as abdominal ultrasound were performed at the same day of blood collection. Results Anti-HEV IgG was positive in 18.8% (15/80) of patients with SM. None of the samples tested positive for anti-HEV IgM or HEV-RNA. Patients with anti-HEV IgG positive presented higher levels of alanine aminotranferase (p = 0.048) and gama-glutamil transferase (p = 0.022) when compared to patients without anti-HEV IgG antibodies. Conclusion This study demonstrates that the seroprevalence of HEV is high in patients with Schistosoma mansoni in Northeastern of Brazil. Past HEV infection is associated with higher frequency of liver enzymes abnormalities. HEV infection and its role on the severity of liver disease should be further investigated among patients with Schistosoma mansoni.


Subject(s)
Humans , Animals , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Schistosomiasis mansoni/epidemiology , Hepatitis E virus/immunology , Hepatitis E/epidemiology , Schistosomiasis mansoni/complications , Brazil/epidemiology , Immunoglobulin G/blood , Immunoglobulin M/blood , Hepatitis Antibodies/blood , Seroepidemiologic Studies , Prevalence , Cross-Sectional Studies , Hepatitis E/complications , Hepatitis E/diagnosis
3.
Mem. Inst. Oswaldo Cruz ; 106(7): 802-807, Nov. 2011.
Article in English | LILACS | ID: lil-606642

ABSTRACT

In this paper, the authors review the literature and share their experience of the principal biological markers of fibrosis for the evaluation of periportal fibrosis (PPF) caused by mansoni schistosomiasis. These biological markers are compared to diagnostic ultrasound (US) scans as means of grading PPF. We also review procollagen type I and III, collagen type IV, laminin, hyaluronic acid (HA), immunoglobulin G, platelets, aspartate aminotransferase to platelet ratio index (APRI) and gamma-glutamyl transpeptidase as markers of the disease. Although there are several good markers for evaluating PPF and portal hypertension, such as HA, platelets or APRI, none can yet replace US. These markers may, however, be used to identify patients at greater risk of developing advanced disease in endemic areas and determine who will need further care and US studies.


Subject(s)
Humans , Hypertension, Portal/diagnosis , Liver Cirrhosis/diagnosis , Liver Diseases, Parasitic/diagnosis , Schistosomiasis mansoni/diagnosis , Biomarkers/blood , Hypertension, Portal/parasitology , Hypertension, Portal , Liver Cirrhosis/parasitology , Liver Cirrhosis , Liver Diseases, Parasitic , Sensitivity and Specificity , Schistosomiasis mansoni
SELECTION OF CITATIONS
SEARCH DETAIL